Abstract
The article presents summarized materials on etiology, pathogenesis, classification, clinical manifestations and treatment of chronic urticuria, The management of patients with this pathology at Dniprovsky Allergological Center was analyzed. For assessment of quality of life SKINDEX-29 questionnaire was used. The questionnaire includes three sections: symptoms, emotions and functions. Physical symptoms include six points: tenderness, heartburn or tingling, itching unpleasant sensations when cotacting with water, skin irritation, sensitivity. The emotional sphere is characterized by such ten points as: concern about the condition of the skin; deppression; feeling of shame; concern that scars can remain after skin disease; feelings about worsening of the skin; anxious mood; embarrassment, feeling of humiliation; skin irritation; rejection of oneself. “Features” section has twelve items: sleep quality; work and hobbies; social activity; sex life; solitude; fatigue; unwillingness to leave home; limiting intimacy with others; complexity in carrying out daily activities; difficulty in expressing feelings; obstruction to create relationships with others; limiting close communication with relatives. Gastrointestinal system was also examined: fibrogastroduodenoscopy with determination of Helicobacter Pylori, ultrasound diagnosis of abdominal organs, the intensity of clinical symptoms was determined on a UAS7 scale. Fifteen patients (including eight women and seven men) were successfully treated with omalizumab. The mean age was 39.1 ± 3.6 years. The average duration of the disease in patients was 5.1 ± 0.9 years. The intensity of symptoms was determined before treatment after the first and second injection of Omalizumab. After the first injection, there was a positive trend. The clinical effect occurred in seventy-two hours. Statistical processing of the study results was performed using Statistica v.6.1® software. (StatSoft, USA). The inclusion of omalizumab is an effective treatment for chronic urticaria in the absence of an effect from antihistamines.
Highlights
Current approaches to the treatment of frequently recurrent urticaria
Condition of the skin; deppression; feeling of shame; concern that scars can remain after skin disease; feelings about worsening of the skin; anxious mood; embarrassment, feeling of humiliation; skin irritation; rejection of oneself
Gastrointestinal system was examined: fibrogastroduodenoscopy with determination of Helicobacter Pylori, ultrasound diagnosis of abdominal organs, the intensity of clinical symptoms was determined on a UAS7 scale
Summary
Розділи СКІНДЕКС-29 функції 0-20,9 21-31,9 32-36,9 ≥ 37 симптоми 0-38,9 39-41,9 42-51,9 ≥ 52. РЕЗУЛЬТАТИ ТА ЇХ ОБГОВОРЕННЯ У всіх пацієнтів відзначалася виражена клінічна симптоматика до початку лікування, що відмічалося уртикарним генералізованим висипом (середня інтенсивність – 3,0 бала) з вираженим свербінням (у середньому 2,9±0,1 бала), що значно погіршувало якість життя пацієнтів (опитувальник СКІНДЕКС-29) – 43,4±4,2. Після обстеження органів шлунково-кишкового тракту виявлені такі коморбідні стани:. Призначалася терапія виявлених супутніх захворювань шлунково-кишкового тракту за рекомендаціями гастроентеролога: ІПП, прокінетики, ерадикація Нelicobacter рylori. Якість життя пацієнтів (опитувальник СКІНДЕКС-29) у середньому становила – 31,9±2,6 бала. Як видно з таблиці 2, після першої ін'єкції висип повністю зник тільки у 2 пацієнтів, але його інтенсивність скоротилася в середньому в 1,7 раза – з 2,9±0,1 бала до 1,7±0,2 бала (p
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.